Award
National Cancer Institute 1R01CA303137-01A1
Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma
Recipient
Dana-Farber Cancer Institute
Award Amount
$721,653.00
Ceiling
$721,653.00
Awarded
June 09, 2026
Identifier
1R01CA303137-01A1
NIH grant awarded to Dana-Farber Cancer Institute to study Protein O-Mannosylation as a therapeutic target in pediatric low-grade glioma driven by KIAA1549-BRAF fusion, with a focus on POMT's role in gliomagenesis and potential drug targeting.
Description
This NIH grant supports research into the role of Protein O-Mannosyltransferase (POMT) in glioma formation related to BRAF-KIAA1549 fusion proteins, focusing on glycosylation as a therapeutic target. The project aims to dissect the mechanism through which the POMT complex enables KIAA1549-BRAF-mediated gliomagenesis and identify strategies for therapeutic intervention, including mouse studies to validate therapeutic potential and evaluate toxicity.